Alert detail
FDA Approval: LYNOZYFIC (LINVOSELTAMAB-GCPT) — Type 1 - New Molecular Entity
What changed
Who’s affected: Hematology billing teams · Effective: July 2, 2025
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.
Audit documentation
Building an audit file?
The Tripwire Audit Pack exports 12 months of Hematology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Not ready to subscribe?
Get the free weekly reimbursement brief for Hematology— the week’s changes and deadlines, delivered to your inbox. No account required.